d-amphetamine

Phase 2Small molecule

NNoven Pharmaceuticals, Inc.

d-amphetamine is one of 85 small molecule programs targeting Substance Abuse. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Substance AbuseActive, not recruiting

Cocaine Use DisorderActive, not recruiting

SchizophreniaActive, not recruiting

Substance AbusePreclinical

Active, not recruiting

Cocaine Use DisorderPhase 1

Active, not recruiting

SchizophreniaPhase 2

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

4 2

Ozempic

Novo Nordisk

Preclinical

1 3

Resotran

Takeda

Preclinical

1 4

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 5

d-amphetamine

NNoven Pharmaceuticals, Inc.

Phase 2

1 6

Zocor

OOrganon and Co

Preclinical

6 7

Depakote

Ibrance

Lunesta

3 10

Comtan

Orion Corporation, Orion Pharma

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Cocaine Use Disorder

NCT05011760

Clinical

Trials by Indication[1]

Cocaine Use Disorder3 trials

Targeting Anhedonia in Cocaine Use Disorder

Completed·UUniversity of Illinois at Chicago·Phase 2·NCT02773212·57 enrolled

Cocaine Use Disorder and Cortical Dopamine

Completed·UUniversity of Pittsburgh·Phase 1·NCT03349606·30 enrolled

[C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2)

Recruiting·RRajesh Narendran·Phase 1·NCT05011760·30 enrolled

Abuse Potential2 trials

A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users

Terminated·BBiotie Therapies Inc.·Phase 1·NCT03200080·26 enrolled

A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users

Completed·NNeurovance, Inc.·Phase 1·NCT02144415·80 enrolled

Drug2 trials

Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer

Completed·JJoshua A. Lile, Ph.D.·Phase 1·NCT02383043·18 enrolled

Differential Responses to Drugs and Sweet Tastes

Completed·UUniversity of Chicago·Phase 1·NCT03810703·93 enrolled

Oral1 trial

Dextroamphetamine-Cocaine Behavioral Intervention - 5

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00000308·54 enrolled

Post-Traumatic Stress Disorder1 trial

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

Recruiting·SStephen Robert Marder·Phase 2·NCT05790239·40 enrolled

8 more indications

Substance Abuse1 trial

Substance Abuse Pre-Treatment Screening Study

Recruiting·TThe University of Texas Health Science Center, Houston··NCT00439049·7,500 enrolled

Tics1 trial

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02515955·76 enrolled

Adult1 trial

Brain Mechanisms in Young Adults

Completed·GGale Richardson·Phase 1·NCT03606473·13 enrolled

Treatment1 trial

Dextroamphetamine as an Adjunct in Cocaine Treatment - 1

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 2·NCT00000304·120 enrolled

Schizophrenia1 trial

Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia

Completed·UUniversity of California, San Diego·Phase 2·NCT04414930·68 enrolled

Completed·NNoven Pharmaceuticals, Inc.·Phase 2·NCT01711021·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for d-amphetamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — d-amphetamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for d-amphetamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Noven Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNoven Pharmaceuticals, Inc.

d-amphetamine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Cocaine Use Disorder3 trials

Abuse Potential2 trials

Drug2 trials

Oral1 trial

Post-Traumatic Stress Disorder1 trial

Substance Abuse1 trial

Tics1 trial

Adult1 trial

Treatment1 trial

Schizophrenia1 trial

Effectiveness1 trial

Function1 trial

Adolescent1 trial

References

Drug Info

Quick Facts

Related News